The notices it replaced
- Reissues: PAR-21-343 Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)
- 2 steps back: PAR-18-951 Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)
- 3 steps back: PAR-18-646 Opportunities for Collaborative Research at the NIH Clinical Center (U01 - Clinical Trial Optional)
- 4 steps back: PAR-15-287 Opportunities for Collaborative Research at the NIH Clinical Center (U01)
- 5 steps back: PAR-13-358 Opportunities for Collaborative Research at the NIH Clinical Center (U01)
- 6 steps back: PAR-13-029 Opportunities for Collaborative Research at the NIH Clinical Center (U01)
Who won it before
63 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $32,815,320 in first-year total cost, median $524,790.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BDCN-L (60)]7
- Special Emphasis Panel[ZCA1 SRB-K (O2)]6
- Special Emphasis Panel[ZHL1 CSR-S (O1)]6
- Special Emphasis Panel[ZCA1 RTRB-4 (O1)]4
- Special Emphasis Panel[ZCA1 TCRB-O (O1)]4
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL5
- CHILDREN'S RESEARCH INSTITUTE3
- JOHNS HOPKINS UNIVERSITY3
- MASSACHUSETTS GENERAL HOSPITAL3
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Proton and hyperpolarized xenon pulmonary MRI at 0.55T1U01HL178354-01 · under PAR-21-343 | CAMPBELL, ADRIENNEMEYER, CRAIG HMUGLER, JOHN P | UNIVERSITY OF VIRGINIA, VA | $659,644 | ZHL1 |
| 2025 | Targeting mutant-MYOD1 driven rhabdomyosarcoma1U01CA298763-01 · under PAR-21-343 | STANTON, BENJAMIN | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $481,052 | ZCA1 |
| 2025 | Cell-Cell Signaling Driving HPV-Induced Respiratory Disease and Vaccine Response1U01CA298630-01 · under PAR-21-343 | WELLS, SUSANNE IWIKENHEISER-BROKAMP, KATHRYN ANN | CINCINNATI CHILDRENS HOSP MED CTR, OH | $95,392 | ZCA1 |
| 2024 | Developing a Translation Pipeline for VHL Mutant Malignancies2U01CA236489-05A1 · under PAR-21-343 | MCDERMOTT, DAVID | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $669,180 | ZCA1 |
| 2024 | E7 TCR-T cell therapy for HPV-associated cancers1U01CA287904-01 · under PAR-21-343 | CAO, JIANGULLEY, JAMES L.HINRICHS, CHRISTIAN | RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ | $642,086 | ZCA1 |
| 2024 | National Succinate Dehydrogenase-deficient GIST Translational Research and Clinical Trial Consortium1U01CA278470-01A1 · under PAR-21-343 | GLOD, JOHN WALTERSICKLICK, JASON KEITH | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $549,618 | ZCA1 |
| 2024 | Microbial, immune, metabolic perturbations by antibiotics (MIME study)2U01AI122285-07A1 · under PAR-21-343 | BLASER, MARTIN JHOLLAND, STEVEN M | RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ | $458,038 | ZCA1 |
| 2024 | Use of Tiered Genetic Sequencing and Specialty Referral for Identifying and Managing Rare Genetic Causes of Chronic Suppurative Respiratory Disease1U01HL172658-01 · under PAR-21-343 | FREEMAN, ALEXANDRAOLIVIER, KENNETH N.SHAPIRO, ADAM | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $423,120 | ZHL1 |
| 2023 | Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancer1U01CA268810-01A1 · under PAR-21-343 | KIBEL, ADAM S | BRIGHAM AND WOMEN'S HOSPITAL, MA | $540,039 | ZCA1 |
| 2023 | Volumetric Real-Time MRI at 0.55 Tesla1U01HL167613-01 · under PAR-21-343 | CAMPBELL, ADRIENNENAYAK, KRISHNA S | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $525,550 | ZHL1 |
| 2023 | Delineation of the natural history of Ollier disease and Muffucci syndrome and investigation of their genetic bases1U01HD107957-01A1 · under PAR-21-343 | MARINI, JOAN CSOBREIRA, NARA | JOHNS HOPKINS UNIVERSITY, MD | $510,889 | CHHD |
| 2023 | Preclinical-clinical trials collaboration to effectively advance new combination therapies for atypical neurofibroma in neurofibromatosis type 11U01CA278474-01 · under PAR-21-343 | CLAPP, DAVID W | INDIANA UNIVERSITY INDIANAPOLIS, IN | $495,641 | ZCA1 |
| 2023 | Hybrid Intelligence for Trustable Diagnosis And Patient Management of Prostate Cancer (HIT-PIRADS)1U01CA268808-01A1 · under PAR-21-343 | BAGCI, ULAS | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $376,880 | ZCA1 |
| 2022 | The molecular and cellular mechanisms of the STAT3 mutation-mediated pulmonary disorder in Autosomal Dominant Hyper IgE Syndrome (AD-HIES)1U01HL156655-01A1 · under PAR-18-951 | BOUCHER, RICHARD CHARLESCHEN, GANG | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $748,549 | ZHL1 |
| 2022 | The role of inflammation in driving leukemogenesis in germline predisposition syndromes1U01CA257666-01A1 · under PAR-18-951 | AGARWAL, ANUPRIYABRESNICK, EMERY HGODLEY, LUCY ANNSPECK, NANCY | UNIVERSITY OF CHICAGO, IL | $707,850 | ZCA1 |
| 2022 | ATTRACT: Assessment of Temporomandibular JoinT MoRphology, Mechanics, And Mechanobiology in Class II and III Target and Surgical Phenotypes1U01DE031512-01 · under PAR-18-951 | LEE, JANICE SYAO, HAI | CLEMSON UNIVERSITY, SC | $620,600 | ZRG1 |
| 2022 | Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer1U01CA268933-01 · under PAR-18-951 | MADAN, RAVI AMRITTONER, MEHMET | MASSACHUSETTS GENERAL HOSPITAL, MA | $611,138 | ZCA1 |
| 2022 | Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors1U01CA268814-01 · under PAR-18-951 | CICHOWSKI, KAREN M | BRIGHAM AND WOMEN'S HOSPITAL, MA | $480,710 | ZCA1 |
| 2022 | A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)1U01CA268813-01 · under PAR-18-951 | CHANG, JENNY C-NLIPKOWITZ, STANLEYMERIC-BERNSTAM, FUNDAWONG, STEPHEN TC | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $448,905 | ZCA1 |
| 2022 | Therapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumors1U01CA268806-01 · under PAR-18-951 | TRINCHIERI, GIORGIOZAROUR, HASSANE M | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $236,768 | ZCA1 |
| 2021 | Microphthalmia, Anophthalmia, and Coloboma Genetic Epidemiology in Children (MAGIC) Study1U01EY032403-01 · under PAR-18-951 | BROOKS, BRIAN PATRICKLUPO, PHILIP | BAYLOR COLLEGE OF MEDICINE, TX | $769,911 | ZRG1 |
| 2021 | Endometrial Basis for Infertility in Women with Recurrent Implantation Failure and Pregnancy Loss1U01HD104482-01 · under PAR-18-951 | DECHERNEY, ALAN H.SPENCER, THOMAS E | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $696,508 | ZRG1 |
| 2021 | Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease1U01HL156620-01 · under PAR-18-951 | DEBAUN, MICHAEL R.FITZHUGH, COURTNEY DFRIEDMAN, DEBRA L.JONES, RICHARD J | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $691,115 | ZHL1 |
| 2021 | Underlying Mechanisms in CADASIL1U01HL151203-01A1 · under PAR-18-951 | BOEHM, MANFREDIRUELA-ARISPE, M. LUISAKOZEL, BETH A | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $654,979 | ZHL1 |
| 2021 | Investigation and Treatment of Undiagnosed Neuroinflammatory Diseases1U01NS120836-01 · under PAR-18-951 | MISHRA, NISCHAYNATH, AVINDRAWILSON, MICHAEL R | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $617,274 | ZNS1 |
| 2021 | Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer1U01CA257638-01 · under PAR-18-951 | SPRATT, DANIEL EIDELBERGSUN, YILUN | CASE WESTERN RESERVE UNIVERSITY, OH | $513,265 | ZCA1 |
| 2020 | The Molecular and Genetic Pathogenesis of LAM2U01HL131022-04 · under PAR-18-951 | EL-CHEMALY, SOUHEILHENSKE, ELIZABETH P | BRIGHAM AND WOMEN'S HOSPITAL, MA | $877,667 | ZHL1 |
| 2020 | Collaborative Research to Explore Genetic Variation and Phenotypic Spectrum of Elastin and Related Genes1U01HL146188-01A1 · under PAR-18-951 | KOZEL, BETH AWILLIAMS, MARC S. | GEISINGER CLINIC, PA | $538,094 | ZHL1 |
| 2020 | Deciphering Clonal Evolution in Hereditary Renal Cell Carcinomas1U01CA247439-01 · under PAR-18-951 | TURAJLIC, SAMRA | FRANCIS CRICK INSTITUTE, LTD | $317,425 | ZCA1 |
| 2019 | Biologic correlatives of chronic GVHD onset1U01CA236229-01 · under PAR-18-646 | LEE, STEPHANIE JPAVLETIC, STEVEN | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $993,954 | ZCA1 |
| 2019 | Developing a Translation Pipeline for VHL Mutant Malignancies1U01CA236489-01 · under PAR-18-646 | LINEHAN, MARSTONMCDERMOTT, DAVIDSRINIVASAN, RAMAPRASAD | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $649,803 | ZCA1 |
| 2019 | Chemoprotection & Immune Remodeling after Hematopoietic Progenitor Cell Gene Therapy for Glioblastoma1U01CA236215-01 · under PAR-18-646 | GERSON, STANTON L.SLOAN, ANDREW E | CASE WESTERN RESERVE UNIVERSITY, OH | $565,191 | ZCA1 |
| 2019 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma1U01CA236220-01 · under PAR-18-646 | GROHAR, PATRICK J | SARC, MI | $473,617 | ZCA1 |
| 2018 | Protective Role of Nonclassical Monocytes in Immunotherapies for Solid Cancers1U01CA224766-01 · under PAR-15-287 | HEDRICK, CATHERINE CKAPLAN, ROSANDRASTRONCEK, DAVID FRANK | LA JOLLA INSTITUTE FOR IMMUNOLOGY, CA | $418,320 | ZCA1 |
| 2018 | Treatment of CGD with the PPAR-gamma agonist, pioglitazone, enhances phagocyte anti-inflammatory and antimicrobial responses1U01AI122269-01A1 · under PAR-15-287 | BRATTON, DONNA LHOLLAND, STEVEN M | NATIONAL JEWISH HEALTH, CO | $166,582 | ZAI1 |
| 2017 | Evaluation of the Safety and Efficacy of Angiotensin 1-7 to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery1U01HL131014-01A1 · under PAR-15-287 | ARAI, ANDREW EHAY, MEREDITHRYAN, LEESWEITZER, NANCY K | UNIVERSITY OF ARIZONA, AZ | $745,065 | ZHL1 |
| 2017 | Immuno-Genetic Basis for Human Disseminated Coccidioidomycosis1U01AI122275-01A1 · under PAR-15-287 | GALGIANI, JOHN NHOLLAND, STEVEN MLUSSIER, YVES A | UNIVERSITY OF ARIZONA, AZ | $573,884 | ZAI1 |
| 2017 | Intravenous delivery of 2-hydroxypropyl-Beta-cyclodextrin for treatment of Niemann-Pick C disease1U01HD090845-01 · under PAR-15-287 | ORY, DANIEL S | WASHINGTON UNIVERSITY, MO | $529,267 | ZRG1 |
| 2017 | SINGLE-CELL TRANSCRIPTOMIC ANALYSIS OF HIV-INFECTED CD4 T CELLS IN BLOOD AND LYMPHOID TISSUE USING PCR-ACTIVATED CELL SORTING1U01AI129206-01 · under PAR-15-287 | ABATE, ADAM R.BORITZ, ELI A | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $481,092 | ZAI1 |
| 2017 | Optical and electromagnetic tracking guidance for hepatic interventions1U01CA202934-01A1 · under PAR-15-287 | MAHMOOD, UMAR | MASSACHUSETTS GENERAL HOSPITAL, MA | $421,989 | ZCA1 |
| 2017 | Bench to bedside: non-invasive treatment of tumors in children1U01CA202947-01A1 · under PAR-15-287 | KIM, PETER CWSHARMA, KARUN VWOOD, BRADFORD J | CHILDREN'S RESEARCH INSTITUTE, DC | $350,585 | ZCA1 |
| 2017 | Genetic Diagnosis of Childhood Growth Disorders1U01HD086838-01A1 · under PAR-15-287 | BARON, JEFFREYJEE, YOUN HEERADOVICK, SALLY | JOHNS HOPKINS UNIVERSITY, MD | $168,712 | ZRG1 |
| 2016 | The Molecular and Genetic Pathogensis of LAM1U01HL131022-01 · under PAR-13-358 | HENSKE, ELIZABETH P | BRIGHAM AND WOMEN'S HOSPITAL, MA | $754,946 | ZHL1 |
| 2016 | Developing a translational pipeline for NF1-mutant malignancies1U01CA202943-01 · under PAR-13-358 | CICHOWSKI, KAREN MWIDEMANN, BRIGITTE | BRIGHAM AND WOMEN'S HOSPITAL, MA | $578,917 | ZCA1 |
| 2016 | Underlying Mechanisms of Vascular Disease1U01HL131019-01 · under PAR-13-358 | BOEHM, MANFREDIRUELA-ARISPE, M. LUISA | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $524,790 | ZHL1 |
| 2016 | Developing clinical, immunologic and radiographic tools to measure the clinical effect of immunotherapy in biochemically recurrent prostate cancer1U01CA202939-01 · under PAR-13-358 | GULLEY, JAMES L.KANTOFF, PHILIP W | SLOAN-KETTERING INST CAN RESEARCH, NY | $470,524 | ZCA1 |
| 2016 | Microbial, immune, metabolic perturbations by antibiotics (MIME study)1U01AI122285-01 · under PAR-13-358 | BLASER, MARTIN J | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $423,750 | ZAI1 |
| 2015 | Choroid Plexus-Directed Gene Therapy for Alpha-Mannosidosis1U01HD079066-01A1 · under PAR-13-358 | WOLFE, JOHN H | CHILDREN'S HOSP OF PHILADELPHIA, PA | $656,702 | ZRG1 |
| 2015 | Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant1U01AI115714-01 · under PAR-13-358 | MASUR, HENRYSTOCK, PETER G | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $601,291 | ZAI1 |
| 2015 | Phase II Study of AAV9-GAA Gene Transfer in Pompe Disease1U01HL121842-01A1 · under PAR-13-358 | BYRNE, BARRY J | UNIVERSITY OF FLORIDA, FL | $601,129 | ZHL1 |
| 2015 | Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative U01 Grant1U01AI115711-01 · under PAR-13-358 | GRINSPOON, STEVEN K.HADIGAN, COLLEEN M | MASSACHUSETTS GENERAL HOSPITAL, MA | $587,655 | ZAI1 |
| 2015 | Beyond the reproductive tract: The future of Y chromosome research1U01HG007587-01A1 · under PAR-13-358 | MUENKE, MAXIMILIANPAGE, DAVID C. | WHITEHEAD INSTITUTE FOR BIOMEDICAL RES, MA | $487,619 | GNOM |
| 2015 | Cerebellar Structure and Function Studies in Very Early Abstinence1U01AA023674-01 · under PAR-13-358 | FEIN, GEORGE | NEUROBEHAVIORAL RESEARCH, INC., HI | $464,024 | ZRG1 |
| 2015 | Mucosal and Systemic Immune Responses to Influenza Virus1U01AI115715-01 · under PAR-13-358 | GREENBERG, HARRY BERNARD | PALO ALTO VETERANS INSTIT FOR RESEARCH, CA | $427,852 | ZAI1 |
| 2015 | PSMA Directed Imaging of Prostate Cancer Focus on Androgen Receptor Dynamics1U01CA183031-01A1 · under PAR-13-358 | DEWEESE, THEODORE LPOMPER, MARTIN G | JOHNS HOPKINS UNIVERSITY, MD | $410,209 | ZCA1 |
| 2015 | Antiretroviral Therapy in Aicardi Goutieres Syndrome1U01HD082806-01 · under PAR-13-358 | GAHL, WILLIAM ALLENVANDERVER, ADELINE LUCIE | CHILDREN'S RESEARCH INSTITUTE, DC | $288,019 | ZRG1 |
| 2015 | Single chain urokinase plasminogen activator (scuPA) for treatment of loculated complicated parapneumonic effusions and empyema1U01HL121841-01A1 · under PAR-13-358 | IDELL, STEVENMASUR, HENRYWOODS, CHRISTIAN J | UNIVERSITY OF TEXAS HLTH CTR AT TYLER, TX | $74,071 | ZHL1 |
| 2014 | MRI-safe 3Dl intracardiac ultrasound catheter for cardiovascular intervention1U01HL121838-01 · under PAR-13-029 | DEGERTEKIN, F. LEVENTLEDERMAN, ROBERT J | GEORGIA INSTITUTE OF TECHNOLOGY, GA | $683,344 | ZHL1 |
| 2014 | Therapeutic Elimination of Stem Cells for Relapsed Pediatric AML1U01CA183030-01 · under PAR-13-029 | LIU, YANGSCHORE, REUVEN J | CHILDREN'S RESEARCH INSTITUTE, DC | $653,666 | ZCA1 |
| 2014 | Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient1U01CA183012-01 · under PAR-13-029 | ZAIA, JOHN A | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $465,641 | ZCA1 |
| 2014 | Integrative molecular imaging and sequencing of prostate cancer1U01CA183027-01 · under PAR-13-029 | CHINNAIYAN, ARUL MLINEHAN, MARSTON | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $416,880 | ZCA1 |
| 2014 | Birth Defects: Moebius syndrome and related facial weakness disorders1U01HD079068-01 · under PAR-13-029 | BROOKS, BRIAN PATRICKENGLE, ELIZABETH C.JABS, ETHYLIN WANGMANOLI, IRINIPIERPAOLI, CARLO | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $388,120 | ZRG1 |
| 2014 | A Phase 1 Dose Escalation Study of Vorinostat in Niemann-Pick C1 Disease1U01HD079065-01 · under PAR-13-029 | MAXFIELD, FREDERICK R.ORY, DANIEL S | WASHINGTON UNIVERSITY, MO | $360,223 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.